Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 9/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5028582 | 0.78 | HTR2A (0.46) | HTR2CHTR2AMAPTTDP1RECQL | |
| SCHEMBL822746 | 0.74 | ALDH1A1 (0.42) | HTR2CHTR2AMAPTTDP1ALDH1A1 | |
| SCHEMBL11611242 | 0.74 | NPC1 (0.57) | MAPTTDP1ALDH1A1KDM4ENPC1 | |
| SCHEMBL7571970 | 0.74 | HASPIN (0.47) | HASPINHTR2CHTR2ARECQLHTR2B | |
| SCHEMBL30848002 | 0.74 | HASPIN (0.47) | HASPINHTR2CHTR2ARECQLHTR2B | |
| SCHEMBL21733174 | 0.74 | ADRA2A (0.54) | HASPINHTR2CHTR2ATDP1RECQL | |
| SCHEMBL31130304 | 0.74 | GRM2 (0.44) | HASPINRECQLKMONPC1 | |
| SCHEMBL31495782 | 0.74 | CYP11B1 (0.42) | HASPINHTR2CHTR2ARECQLHTR2B | |
| SCHEMBL23206121 | 0.73 | HTR2C (0.46) | HASPINHTR2CHTR2AHTR2BKMO | |
| SCHEMBL13217 | 0.72 | RECQL (0.61) | RECQLKMOTSHRHSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396856-B2 | Benzopyran analogs and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2008-07-08 | — | — | US | disclosed |
| US-20050209314-A1 | Novel benzopyran analogs and their use for the treatment of glaucoma | ALCON, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6933392-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-08-23 | — | — | US | disclosed |
| US-6884816-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-26 | — | — | US | disclosed |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | MAY JESSE A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2003-09-25 | — | — | US | disclosed |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HASPIN 1963/4885HTR2C 2661/4885HTR2A 3176/4885 |
| US-20050209314-A1 | Novel benzopyran analogs and their use for the treatment of glaucoma | PGC, PDE3A, PTGIS | HASPIN 1144/4885HTR2C 3277/4885HTR2A 2528/4885 |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HASPIN 1963/4885HTR2C 2661/4885HTR2A 3176/4885 |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HASPIN 1963/4885HTR2C 2661/4885HTR2A 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.